Cue Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cue Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q3 2024.
  • Cue Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$8.66M, a 21.3% increase year-over-year.
  • Cue Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$44.6M, a 14% increase year-over-year.
  • Cue Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$50.7M, a 4.3% increase from 2022.
  • Cue Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$53M, a 20% decline from 2021.
  • Cue Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$44.2M, a 1.39% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$44.6M -$8.66M +$2.35M +21.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$47M -$10.2M +$3.01M +22.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$50M -$12.3M +$762K +5.81% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$50.7M -$13.4M +$1.16M +7.94% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$51.9M -$11M -$50K -0.46% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$51.8M -$13.2M +$23K +0.17% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$51.9M -$13.1M +$1.15M +8.04% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$53M -$14.6M -$6.21M -74% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$46.8M -$11M +$2.04M +15.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$48.8M -$13.2M -$2.93M -28.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$45.9M -$14.3M -$1.75M -14% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$44.2M -$8.38M +$2.72M +24.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-21
Q3 2021 -$46.9M -$13M -$2.96M -29.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$43.9M -$10.3M +$554K +5.11% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$44.5M -$12.5M +$313K +2.44% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$44.8M -$11.1M -$2.18M -24.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 -$42.6M -$10M -$3.04M -43.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$39.6M -$10.8M -$1.31M -13.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$38.2M -$12.8M -$1.55M -13.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$36.7M -$8.92M +$2.68M +23.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$39.4M -$6.99M +$5.57M +44.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$44.9M -$9.52M -$2.22M -30.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$42.7M -$11.3M -$3.74M -49.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$39M -$11.6M -$1.16M -11.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$37.8M -$12.6M -$7.53M -150% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$30.3M -$7.3M -$2.89M -65.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$27.4M -$7.52M -$4.17M -125% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$23.2M -$10.4M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$5.03M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$4.41M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$3.35M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.